The influence of exendin and GLP-1 on VCAM-1 and ICAM-1 production in endothelium stimulated by TNF-α and glycated albumin
- 1 Department of Biochemistry, Medical University of Silesia, Katowice, Poland
- 2 Department of Biochemistry, Medical University of Silesia, Katowice, Poland
- 3 Department of Biochemistry, Medical University of Silesia, Katowice, Poland
Abstract
A growing body of evidence indicates that incretins may have pleiotropic beneficial effects beyond lowering glucose blood concentration. The effect of GLP-1 and exendin-4 on coronary arteries endothelium in diabetic and obese individuals has been studied widely. TNF- a is one of adipocytokines. The aim of our study was to evaluate the influence of glycated albumin (GlyAlb; 100; 500 and 1000 mg/L) and proinflammatory cytokine, TNF- α (2.5 and 10 ng/mL), on expression of ICAM-1 and VCAM-1 in cultured human endothelial cells derived from coronary arteries. The next goal of the study was to evaluate the influence of GLP-1 (10 nM and 100 nM) and its analogue, exendin-4 (1 nM and 10 nM), on the expression of ICAM-1 and VCAM-1 in these cell line. TNF- a statistically significantly increased VCAM-1 production by endothelial cells, whereas GlyAlb statistically significantly augmented the expression of both tested adhesion mole- cules. Exendin-4 and GLP-1 statistically significantly reduced the expression of VCAM-1 in endothelial cells stimulated by GlyAlb in dose-de- pendent manner. When TNF- a was used as the stimulant only exendin-4 in the concentration of 10 nM statistically significantly reduced the expression of VCAM-1. Studied incretins in their both concentrations statistically significantly reduced the expression of ICAM-1 in endothelial cells stimulated by GlyAlb. The influence of TNF- a on the expression of ICAM-1 was statistically significantly reduced by both concentrations of exendin-4 but only by the higher concentration of GLP-1. The results of our present study indi cate that incretins may present a group of agents developing pleiotropic effects beyond the reduction of blood glucose concentration. Their vaso-protective and cardioprotective action may be of importance in diabetic and obese individuals.
- James, P.T., Rigby, N., Leach, R. and International Obe- sity Task Force (2004) The obesity epidemic, metabolic syndrome and future prevention strategies. European Journal of Cardi-ovascular Prevention and Rehabilitation, 11, 3-8. doi:10.1097/01.hjr.0000114707.27531.48
- Koce?ak, P., Chudek, J. and Olszanecka-Glinianowicz, M. (2012) Prevalence of metabolic syndrome and insulin re- sistance in overweight and obese women according to the different diagnostic criteria. Minerva Endocrinologica, 37, 247-254.
- Pichi, A., Gao, X., Belmadani, S., Potter, B.J., Focardi M., Chilian, W.M. and Zhang, C. (2006) Tumor necrosis fac- tor-a induces endothelial dysfunction in the prediabetic metabolic syndrome. Circulation Research, 99, 69-77. doi:10.1161/01.RES.0000229685.37402.80
- Vykoukal, D. and Davies, M.G. (2011) Vascular biology of metabolic syn-drome. Journal of Vascular Biology, 54, 819-831. doi:10.1016/j.jvs.2011.01.003
- Yudkin, J.S. (2007) In-flammation, obesity, and the meta- bolic syndrome. Hormone and Metabolic Research, 39, 707-709. doi:10.1055/s-2007-985898
- Thorpe, S.R. and Baynes, J.W. (1996) Role of Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging, 9, 69-77. doi:10.2165/00002512-199609020-00001
- Brubaker, P.L. (2007) Incretin-based therapies: Mimetics versus protease inhi-bitors. Trends in Endocrinology and Metabolism, 18, 240-245. doi:10.1016/j.tem.2007.06.005
- Lovshin, J.A. and Drucker, D.J. (2009) Incretin-based therapies for type 2 diabetes mellitus. Nature Reviews Endocrinology, 5, 262-269. doi:10.1038/nrendo.2009.48
- Ban, K., Noyan-Ashraf, M.H., Hoefer, J., Bolz, S.S., Drucker, D.J. and Husain, M. (2008) Cardioprotective and vasodilatory actions of gluca-gon-like peptide 1 recep- tor are mediated through both gluca-gon-like peptide 1 re- ceptor-dependent and -independent pathways. Circulation, 117, 2340-2350. doi:10.1161/CIRCULATIONAHA.107.739938
- Ishibashi, Y., Matsui, T., Takeuchi, M. and Yamagishi, S. (2010) Gluca-gon-like peptide-1 (GLP-1) inhibits advan- ced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by sup- pressing AGE receptor (RAGE) expression. Biochemical and Biophysical Research Communications, 391, 1405- 1408. doi:10.1016/j.bbrc.2009.12.075
- MacIsaac, R.J. and Jerums G. (2011) Intensive glucose control and cardiovascular outcomes in type 2 diabetes (April 2010). Heart, Lung and Circulation, 20, 647-654. doi:10.1016/j.hlc.2010.07.013